Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6584
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe ; day:23 ; month:5 ; year:2016 ; pages:1-13
Rheumatology and therapy ; (23.5.2016), 1-13
- Creator
-
Thakur, Kunal
- Contributor
-
Biberger, Anna
Handrich, Alexandra
Rezk, Mourad Farouk
SpringerLink (Online service)
- DOI
-
10.1007/s40744-016-0035-1
- URN
-
urn:nbn:de:1111-2016052420838
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Thakur, Kunal
- Biberger, Anna
- Handrich, Alexandra
- Rezk, Mourad Farouk
- SpringerLink (Online service)
Other Objects (12)
Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Correction to: GP2015: An Etanercept Biosimilar
Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
Afebriles Erysipel unter Etanercept-Therapie
Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
Etanercept and venous thromboembolism: a case series
Perispinal etanercept: Potential as an Alzheimer therapeutic
Etanercept-Induced Anti-Glomerular Basement Membrane Disease
Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Correction to: GP2015: An Etanercept Biosimilar
Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
Afebriles Erysipel unter Etanercept-Therapie
Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
Etanercept and venous thromboembolism: a case series
Perispinal etanercept: Potential as an Alzheimer therapeutic
Etanercept-Induced Anti-Glomerular Basement Membrane Disease
Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Correction to: GP2015: An Etanercept Biosimilar
Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
Afebriles Erysipel unter Etanercept-Therapie
Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
Etanercept and venous thromboembolism: a case series
Perispinal etanercept: Potential as an Alzheimer therapeutic